Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
55.75
+0.12 (0.22%)
Jun 10, 2026, 10:59 AM EDT - Market open
Royalty Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 468.26 | 1,324 | 1,331 | 1,700 | - | - |
Depreciation & Amortization | 1.17 | 3.85 | - | - | - | - |
Stock-Based Compensation | 121.99 | 289.89 | 2.34 | 2.36 | - | - |
Other Adjustments | -708.37 | -2,466 | -1,601 | -1,921 | - | - |
Changes in Accounts Payable | -5.08 | -13.93 | -2.29 | 6.24 | - | - |
Changes in Accrued Expenses | -85.52 | 8.93 | 46.38 | -2.48 | - | - |
Changes in Other Operating Activities | 3,538 | 2,478 | 2,778 | 2,989 | 2,144 | 2,018 |
Operating Cash Flow | 2,612 | 2,490 | 2,769 | 2,988 | 2,144 | 2,018 |
Operating Cash Flow Growth | -3.28% | -10.08% | -7.32% | 39.36% | 6.27% | -0.84% |
Purchases of Investments | -2,667 | -2,202 | -2,822 | -2,140 | -2,575 | -3,647 |
Proceeds from Sale of Investments | 48.06 | 566.5 | 118.36 | 25.83 | 1,546 | 1,776 |
Payments for Business Acquisitions | -74.42 | -74.42 | - | - | - | - |
Other Investing Activities | 102.25 | 96.2 | 25.68 | 41.84 | - | 0.52 |
Investing Cash Flow | -2,596 | -1,614 | -2,678 | -2,073 | -1,029 | -1,870 |
Short-Term Debt Issued | - | 1,275 | - | 350 | - | - |
Short-Term Debt Repaid | - | -1,275 | - | -350 | - | - |
Long-Term Debt Issued | 1,954 | 1,954 | 1,471 | - | - | 1,273 |
Long-Term Debt Repaid | - | -1,000 | - | -1,000 | - | - |
Net Long-Term Debt Issued (Repaid) | 1,954 | 954.48 | 1,471 | -1,000 | - | 1,273 |
Repurchase of Common Stock | -568.7 | -1,227 | -229.65 | -304.76 | - | - |
Net Common Stock Issued (Repurchased) | -568.7 | -1,227 | -229.65 | -304.76 | - | - |
Common Dividends Paid | -387.39 | -378.25 | -376.47 | -358.33 | -333.32 | -285.18 |
Other Financing Activities | -515.73 | -534.81 | -503.97 | -485.67 | -611.53 | -602.24 |
Financing Cash Flow | -517.34 | -1,186 | 361.15 | -2,149 | -944.86 | 385.11 |
Net Cash Flow | -501.33 | -310.33 | 452.02 | -1,234 | 169.7 | 532.37 |
Free Cash Flow | 2,612 | 2,490 | 2,769 | 2,988 | 2,144 | 2,018 |
Free Cash Flow Growth | 4.91% | -10.08% | -7.32% | 39.36% | 6.27% | -0.84% |
FCF Margin | 107.02% | 104.69% | 122.33% | 126.89% | 95.83% | 88.12% |
Free Cash Flow Per Share | 6.03 | 4.41 | 4.66 | 4.96 | 4.90 | 4.86 |
Levered Free Cash Flow | 6,230 | 4,202 | 5,153 | 3,128 | 2,187 | 3,910 |
Unlevered Free Cash Flow | 5,037 | 4,036 | 4,115 | 4,485 | 2,451 | 3,448 |